Efforts to maintain the quality of Life for patients with malignant lymphoma undergoing chemotherapy

Efforts to maintain the quality of Life for patients with malignant lymphoma undergoing chemotherapy - Maintenance of QOL for patients with malignant lymphoma

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000026758

Enrollment

Registered

2017-03-31

Start date

2017-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant lymphoma

Interventions

Patients with B-cell malignant lymphoma were treated by R-CHOP therapy with or without BCAA. [group 1]therapy with 2 pack of the BCAA-enriched supplement (aminofeel, TERUMO) [group 2]therapy with

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)B-cell malignant lymphoma 2)No dementia 3)Patients with informed consent by self judgment

Exclusion criteria

Exclusion criteria: 1)multiple organ failure 2)progressive diseases during R-CHOP therapy

Design outcomes

Primary

Measure	Time frame
Evaluation of muscle mass by body composition analyzer, InBody	—

Secondary

Measure	Time frame
Patient characteristics including age,sex,pathology,staging,chemotherapy effets. Side effects related with chemotherapy. Questionnaire survey with SF-36.	—

Countries

Japan

Contacts

Public ContactNaomi Shimizu

Toho University Medical Center Sakura Hospital Center for Diabetes, Metabolism and Endocrinology

naomis-cib@umin.ac.jp043-462-8811

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026